Loading…
Loading…
Base rate computed from analyst-asserted responds_to: edges in the reverse direction (target-country → issuer-country) for prior issuer-actions on the same target. Modal type + lag percentiles only — not a model output. Treat as a historical anchor for sizing counter-response scenarios, not a forecast in itself.
The Pharma 232 proclamation is the third standalone sectoral Section 232 tariff in the post-2024 reset, after 2025-02-11-us-section-232-steel-aluminum-global-tariff-reinstatement, 2025-07-30-us-section-232-copper-tariff-proclamation-10962, and the parallel 2026-01-14-us-section-232-semiconductor-proclamation. It is the first standalone pharma sectoral-tariff action in the IPTM register and one of the largest single-instrument tariff actions by trade-flow exposure: patented pharmaceutical and API imports run on the order of USD 200bn+ per year in the relevant covered scope.
Investigation timeline:
investigation into pharmaceuticals and active pharmaceutical ingredients on national-security grounds.
findings. Cited rationale: ~53% of US-distributed patented pharmaceutical product and ~85% of patented APIs sourced abroad as of 2025.
Annex III at 12:01 a.m. EDT.
closes.
the full 100% rate.
The supply-side coercion lever for MFN pricing. The proclamation is operationally inseparable from 2025-05-12-us-trump-mfn-drug-pricing-eo14273 (the demand-side MFN-pricing executive order). EO 14273 directs HHS, USTR, and Commerce to push US drug prices toward the lowest international benchmark; by April 2026 17 large manufacturers had signed bilateral MFN agreements. The 232 proclamation hard-wires the carrot/stick mechanic: a manufacturer that signs an HHS MFN agreement and an approved onshoring plan pays 0% until January 2029. Those that do neither pay 100%. Those that take the onshoring lane only pay an incremental +20% transition rate. The structure converts a price negotiation that previously relied on rhetorical pressure into one backed by a tariff schedule. This is why we set responds_to: 2025-05-12-us-trump-mfn-drug-pricing-eo14273 — the EO is the political genesis, the proclamation is the enforcement instrument.
Country incidence. The country-tier table is unusually explicit for a Section 232 tariff, which historically applied global flat-rate or country-by-country quota architectures rather than named concessionary partners. The 15% EU/Japan/Korea/Switzerland/ Liechtenstein band materially reduces incidence on the largest upstream pharma jurisdictions:
EWL has direct read-through.
US-bound pharma exports by value (Pfizer, Lilly, AbbVie, J&J, MSD all have major Irish API/finished-dose facilities). EIRL has high concentration in pharma.
Bioepis biosimilars sit in the 0% carve-out anyway.
reflecting the bilateral UK-US pharmaceutical agreement.
via the generics carve-out, but India's emergent branded /biosimilar export is hit at the full base rate. Less exposed than headline numbers suggest given the generics exemption.
hub for several US-listed companies.
Generic/biosimilar carve-out is the key constraint on inflation pass-through. In 2024 ~91% of US prescriptions were filled by generics. The carve-out means the bulk of dispensed volume is untariffed; the 100% rate falls on the patented brand surface, which is small in unit terms but the dominant share of revenue. So the macro inflation transmission is muted while the margin-shock for branded innovators is substantial, depending on tier eligibility.
direct exposure to the 15% tier; the gap between this rate and the 100% base rate is the implicit "deal premium" priced into European pharma equity from April onward.
0% carve-out for combined onshoring + MFN signature is decisive: manufacturers that have not signed MFN agreements by 31 July 2026 face 100% on patented imports unless their jurisdiction has a 15% deal. Expect a surge of bilateral MFN-pricing deals between April and July 2026, materially expanding the EO 14273 deal-count beyond the 17 announced through April 2026.
surcharge is meaningfully cheaper than 100% — so any manufacturer with a credible US capacity expansion plan will pursue Commerce approval. Watch for Lilly, Pfizer, AbbVie, Merck, BMS Indiana/Massachusetts/North Carolina capex announcements in 2026 H2.
insulates India's bulk export volume but Indian branded / biosimilar exporters are hit at 100%. INDA / EPI fund exposure is muted but not zero. SGP exposure is via US-listed biopharma manufacturing footprints rather than Singapore-listed names.
ATR) flagged the proclamation as inflationary for patients; the structure of the carve-outs (orphan, plasma, generics, biosimilars) was clearly designed to insulate the most politically sensitive prescription-volume categories. Net CPI impact should be modest, concentrated in the branded drug bucket.
base than IEEPA-emergency tariffs, which limits the V.O.S.-Selections-style challenge surface. The use-based carve-outs and country-tier deals may attract Administrative Procedure Act / equal-protection challenges from excluded jurisdictions, but the §232 frame is durable.
Annex III but the public summary does not enumerate the 17 companies. Probable overlap with the 17 EO-14273 MFN-deal signatories (Lilly, Pfizer, BMS, AbbVie, Merck, AstraZeneca, Regeneron, plus 10 others) but should be confirmed when CBP publishes implementing guidance. Partial confirmation (2026-08-12): AbbVie is confirmed as one of the 17 named companies, per its own 12 January 2026 agreement with the administration — $100bn pledged to US R&D/manufacturing capex, MFN pricing for select drugs (incl. Humira) via Medicaid and the TrumpRx platform, in exchange for a three-year exemption from the patented-pharmaceutical duty. AbbVie separately concluded a company-specific Section 232 agreement with Commerce dated 20 March 2026. This is the supply-side/demand-side mechanic described above operating on a named company rather than the generic tier structure.
listed in the Orange Book / Purple Book" is a regulatory reference rather than a tariff schedule code; CBP will need to publish a crosswalk to HTSUS codes for customs enforcement.
for an "onshoring plan" — investment dollar floor, capacity share, timeline — are not in the public proclamation text and are a key driver of which manufacturers can capture the +20% transition rate vs the 100% base rate.
(2025-04-02-us-trump-reciprocal-tariff-regime).** Whether the Section 232 pharma rate stacks with the reciprocal tariff baseline or supersedes it for in-scope products is not clarified in the proclamation.
across all 27 member states under a single trade-deal track; Ireland's outsized US-pharma role makes the practical EU incidence concentrated rather than uniform.